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Tau phosphorylationAlzheimer's disease (AD) is a neurodegenerative pathologywith relevant unmet therapeutic needs. Both natural
aging and AD have been associated with a signiﬁcant decline in the omega-3 polyunsaturated fatty acid
docosahexaenoic acid (DHA), and accordingly, administration of DHA has been proposed as a possible treatment
for this pathology. However, recent clinical trials inmild-to-moderately affected patients have been inconclusive
regarding the real efﬁcacy of DHA in halting this disease. Here, we show that the novel hydroxyl-derivative of
DHA (2-hydroxydocosahexaenoic acid — OHDHA) has a strong therapeutic potential to treat AD. We demon-
strate that OHDHA administration increases DHA levels in the brain of a transgenic mouse model of AD
(5xFAD), as well as those of phosphatidylethanolamine (PE) species that carry long polyunsaturated fatty acids
(PUFAs). In 5xFADmice, administration of OHDHA induced lipidmodiﬁcations thatwere paralleledwith a reduc-
tion in amyloid-β (Αβ) accumulation and full recovery of cognitive scores. OHDHA administration also reduced
Aβ levels in cellular models of AD, in association with alterations in the subcellular distribution of secretases
and reduced Aβ-induced tau protein phosphorylation as well. Furthermore, OHDHA enhanced the survival of
neuron-like differentiated cells exposed to different insults, such as oligomeric Aβ and NMDA-mediated neuro-
toxicity. These results were supported by model membrane studies in which incorporation of OHDHA into
lipid-raft-like vesicles was shown to reduce the binding afﬁnity of oligomeric and ﬁbrillar Aβ to membranes.
Finally, the OHDHA concentrations used here did not produce relevant toxicity in zebraﬁsh embryos in vivo. In
conclusion, we demonstrate the pleitropic effects of OHDHA that might prove beneﬁcial to treat AD, which
suggests that an upstream event, probably the modulation of the membrane lipid composition and structure,
inﬂuences cellular homeostasis reversing the neurodegenerative process. This Article is Part of a Special Issue
Entitled: Membrane Structure and Function: Relevance in the Cell's Physiology, Pathology and Therapy.
© 2013 Elsevier B.V. All rights reserved.ecursor protein; PS1, presenilin-
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ights reserved.1. Introduction
Alzheimer's disease is a neurodegenerative disorder that produces se-
vere cognitive impairment as it progresses. This pathology is the main
neurological cause of dementia and it is suffered by 36 million people
worldwide, elderly adults in most cases (World Alzheimer Report
2011). Unfortunately, there are still no effective treatments that mitigate
the neurological deﬁcits associated with AD. Currently, these patients
may be treated with two classes of approved drugs that ameliorate the
symptoms of AD, acetylcholinesterase inhibitors and NMDA receptor an-
tagonists, although their clinical efﬁcacy is considered to be very limited
[1]. Other promising therapeutic approaches have been proposed for
AD, such as statins and non-steroidal anti-inﬂammatory drugs, although
they have yet to offer conclusive results in clinical trials [2–4].
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it is tightly involved in the functioning of the central nervous system
(CNS) [5], particularly in neurogenesis, synaptogenesis and synaptic
transmission [6,7]. This fatty acid is obtained through the diet and its de-
ﬁciency is associatedwith age-related cognitive decline andwith neuro-
degenerative diseases, such as AD [8,9]. In recent years, PUFAs like DHA
have gained much attention due to promising results that suggest they
may be useful to treat AD. In this sense, several studies have demon-
strated that oral intake of DHA or ﬁsh oil reduces AD-associated brain
pathology, for instance, improving cognitive deﬁcits, protecting against
synaptic degeneration and lowering Aβ levels in transgenic AD mouse
models [10–13]. Moreover, these results are supported by epidemiolog-
ical studies indicating an inverse relationship between DHA intake and
AD incidence, which correlate high DHA levels with reduced risk of cog-
nitive dysfunction [14,15]. However, direct administration of DHA in
clinical trials only showed improved cognition of a small subgroup of
patients with verymild cognitive dysfunction and therewas no clear ef-
fect inmost patients [16,17], even thoughDHAadministration improves
the physiological, but not pathological, age-related cognitive decline
[18].
In this context, there would appear to be a link between AD and
lipid alterations in neuronal membranes, especially diminished DHA
levels. Therefore, molecules that are effective in restoring DHA and
normalizing the membrane lipid composition could constitute
therapeutic tools to treat AD. In the present work, we show that
OHDHA regulatesmembrane lipid composition and structure, cell signal-
ing and, additionally, it improves cognitive scores in animalmodels of AD
[19], thereby representing a novel therapeutic candidate for the treat-
ment of AD. This DHA derivative bears a hydroxyl group on the α-
carbon that impedes its β-oxidation and increases its half-life in lipid
membranes. Interestingly, natural DHA hydroxyl derivates are also pro-
duced in the brain, such as neuroprotectin D1 (NPD1), and like DHA,
NPD1 is also strongly diminished in the brain of AD patients [20]. The bi-
ological function of this molecule has been related tomultiple neuropro-
tective effects, such as antioxidant, anti-inﬂammatory and anti-apoptotic
roles. NPD1 also downregulates Aβ peptide production bymodulating β-
andα-secretase activities, and it favors neuronal survival against Aβ tox-
icity [20,21]. In the present work we found that OHDHA administration
leads to enrichment of membranes in long PUFAs, which is associated
with neuronal survival and neuroregeneration, so that OHDHA mimics
the effects of NPD1. These changes in membrane lipid composition
could facilitate the maintenance of a functional cell membrane structure
that, in the case of AD, may reverse neurons from a pathological to a
healthy condition [22]. Speciﬁcally, we show that by downregulating
Aβ generation and Aβ-induced tau protein hyperphosphorylation,
OHDHA promotes neuroprotection, and cell survival against different
knownAD-associated insults. In addition, this compound can also induce
neuron stem cell proliferation via molecular and cellular mechanisms
that remain largely unknown [19] and patients. Thus, OHDHA-induced
neuron survival and proliferation should lead to improved cognition in
AD models [19] and patients. In conclusion, OHDHA is presented here
as a novel therapeutic candidate for the treatment of the AD-related
neurodegeneration.
2. Materials and methods
2.1. Transgenic mice and treatments
A double transgenic PS1/APP mouse model was used in this work
(5xFAD; line Tg6799) that harbors ﬁve human mutations associated to
familial AD: the Swedish (K670N/M671L), Florida (I716V) and London
(V717I) mutations in APP (amyloid precursor protein); and a human
mutated PS1 (presenilin 1) harboring theM146L and L286V clinicalmu-
tations. Both these transgenes are expressed under control of the Thy-1
promoter. These mice display cognitive decline from 4 months of age
[23]. These transgenic 5xFAD and wild type (WT)mice were purchasedfrom Jackson Laboratories (USA), and they weremaintained on a B6/SJL
hybrid genetic background (C57BL/6 x SJL) by crossing heterozygous
transgenic micewith B6/SJLWT (F1) breeders. All animals were housed
at a controlled temperature and humidity (22 ± 2 °C; 70% humidity)
on a 12 h–12 h light–dark cycle, and theywere provided a standard lab-
oratory diet ad libitum (Panlab A03; Barcelona, Spain).
WT and transgenic 5xFAD male mice were orally administered
OHDHA (Lipopharma Therapeutics; Palma de Mallorca, Spain) dis-
solved in 5% ethanol at a dose of 15 mg/kg·day or the vehicle solution
alone (5% ethanol; 15 ml/kg·day). These treatments started when the
mice reached 3 months of age (dosed 5 days/week) and theywere con-
tinued until themice reached 7 months of age. During the last month of
treatment, all the animals were submitted to a hypocaloric diet neces-
sary to perform the selected behavioral spatial learning and memory
test (food craving test in a radial armmaze) [24]. The results concerning
the radial armmaze test have been reported previously [19], and a sum-
mary table (containing more relevant ﬁndings and total number of an-
imals that were used for the test) has been also included in the
discussion section of the present work (Table 4). Following the behav-
ioral test, themicewere kept on normal diet (and treatment) for an ad-
ditional week, after which they were euthanized, and their brain was
removed immediately and dissected down the midline on a cold sur-
face. Having removed the cerebellum, each cerebellum-free hemibrain
was frozen in liquid nitrogen and stored at−80 °C. A total number of
9 animals were used in this work: 3 vehicle-treated WT, 3 vehicle-
treated 5xFAD and 3 OHDHA-treated 5xFAD mice. All the protocols
employedwere approved by the Bioethical Committee of the University
of the Balearic Islands, and they are in agreement with national and in-
ternational regulations on animal welfare.
2.2. Lipid extraction and determination of cholesterol content
One hemi-brain from each animal was homogenized in a guanidine-
salt buffer (RLTBuffer; Qiagen) at 1:20 (w:v) using a blade homogenizer
(Polytron PT3100). The samples were then incubated at room tempera-
ture for 10 min and centrifuged for 5 min (10,000 g, 4 °C). The resulting
supernatant was recovered, aliquoted and stored at −80 °C. Lipids
were extracted using Bligh and Dyer's method [25]. The recovered
organic phasewas stored under aN2 atmosphere at−80 °C. The choles-
terol (Cho) content was determined as described previously [26]. Brief-
ly, lipid extracts were evaporated under argon ﬂow for at least 2 h and
then resuspended in isopropanol. Total cho was measured in an aliquot
(10 μl) using an enzymatic colorimetric kit (Biosystems; Barcelona,
Spain) and determined through the appearance of a product absorbing
at 500 nm.
2.3. Sphingolipid and phospholipid lipidomic analysis
Lipidomic studies were performed as described previously [27,28].
Liquid cromatography/mass spectrometry (LC/MS) analysis was per-
formed on aWaters Aquity UPLC system connected to aWaters LCT Pre-
mier orthogonal accelerated time of ﬂight mass spectrometer (Waters),
operated in positive electrospray ionization mode. Full scan spectra
from50 to 1500 Dawere acquired and individual spectrawere summed
to provide data points each 0.2 s. Mass accuracy and reproducibility
were maintained by using an independent reference spray via
LockSpray interference. The analytical column was a 100 × 2.1 mm
inner diameter, 1.7 μm C8 Acquity UPLC bridged ethylene hybrid
(Waters), thermostated at 30 °C. The two mobile phases both
contained 5 mM ammonium formate: phase A, MeOH/H2O/HCOOH
(74:25:1, v/v); and phase B: MeOH/HCOOH (99:1, v/v). Quantiﬁcation
was carried out on 50mDawindows using the extracted ion chromato-
gram of each compound, and the linear dynamic range was determined
by injecting standard mixtures. Positive identiﬁcation of compounds
was based on accurate mass measurement, with an error of b5 ppm,
and LC retention times compared to that of standards (±2%).
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LC/MS/MS with a system consisting of a Waters Alliance 2690 LC pump
equipped with an autosampler and connected to a Quattro LC triple-
quadrupolemass spectrometer (Micromass,Manchester, UK). Separation
was achieved on a Purospher STAR-RP-18 column (125 × 2 mm, 5 μm;
Merck) using the same mobile phases as described above with a ﬂow
rate of 0.3 ml min−1. The gradient used was: 0.0 min, 50% B; 2 min,
50% B; 7 min, 100% B; 17 min, 100% B; 19 min, 50% B; and 26 min, 50%
B.MS/MSdetectionwasperformedwith an electrospray interface operat-
ing in the positive ion mode acquiring the following selected reaction
monitoring transitions: C17 d-erythro-dihydrosphingosine-1-phosphate,
368–252 Da, collision energy 18 eV; and S1P, 380–264 Da, collision
energy 16 eV.
2.4. Cell culture and treatments
2.4.1. Cell lines
Mouse neuroblastoma N2a cells stably transfected with human
Swedish-mutated APP, also called N2aSw (kindly provided by Gopal
Thinakaran; University of Chicago, USA), were maintained in a 1:1
(v:v) mixture of Dulbecco's Modiﬁed Eagle Medium (DMEM) and
OPTI-MEM (Invitrogen) supplemented with 5% fetal bovine serum
(FBS; Sigma), penicillin/streptomycin (PAA) and G-418 (ﬁnal concen-
tration, 0.2 mg/ml). N2aSw cellswere transfectedwith PS1-GFP (kindly
provided by Dr Christoph Kaether; Leibniz Institute for Age Research;
Germany) or BACE1 (kindly provided by Jochen Walter; University of
Bonn; Germany) cDNAs using the calcium phosphate method [29].
Human neuroblastoma SH-SY5Y cells were maintained in DMEM
Hams F12 (Invitrogen) supplemented with 10% FBS (Sigma), penicillin/
streptomycin (PAA), non-essential aminoacids (Sigma) and 2 mM
L-glutamine (Sigma). Differentiation of these cells to a neuron-
like phenotype was carried out as described previously [30]. Brieﬂy,
cells were plated in poly-L-Lysine pre-coated dishes and 24 h later,
the medium was replaced with fresh medium supplemented with
10 μM retinoic acid (Sigma). The cells were then incubated in the dark
for 5 days and the medium was replaced with medium without
serum and supplemented with 50 ng/ml of human brain-derived
neurotrophic factor (hBDNF; Alomone Labs; Tel Aviv, Israel). Finally,
the cells were incubated for 6 days to complete differentiation.
Embryonalmultipotent stem P19 cells were cultured inα-Minimum
Essential Medium (αMEM; Sigma) containing 10% FBS (Sigma) and
penicillin/streptomycin (PAA). Differentiation of P19 cells to a neuron-
like phenotype was carried out as described previously [31]. Brieﬂy,
differentiation was induced by 300 nM retinoic acid for 48 h, followed
by sub-culturing 1:4 in the presence of 300 nM retinoic acid for another
48 h. Incubation with retinoic acid was performed in the dark. Cell
clusters were then seeded 1:4 in 6-well plates for an additional 24 h
to complete the differentiation process.
MDCK cells, stably expressing the human APP-GFP fusion protein
were cultured in DMEM supplemented with 5% FBS (Sigma) and
penicillin/streptomycin (PAA). All cell lines were incubated in a 5%
CO2 atmosphere at 37 °C.
2.4.2. Hydroxylated lipids, Aβ and NMDA treatments
Stock solutions containing 100 mMOHDHA in DMSO were used for
cell treatments. DMSO was diluted to be below 0.1% in the medium.
N2aSw cells were incubated in the presence or absence of 5, 10 or
50 μM OHDHA for 24 h. Neuron-like differentiated SH-SY5Y cells were
exposed to oligomeric Aβ (5 μM) for 24 h in the presence or absence
of OHDHA (5 and 10 μM). Neuron-like differentiated P19 cells were
treated for 24 h with OHDHA (10 μM), and then for 30 min with
NMDA (10 mM, Sigma) in fresh media containing glycine (530 μM,
Sigma) and calcium (10 mM, Sigma). Finally, APP-GFP MDCK cells
were treated for 72 h with OHDHA at 1, 3, 10, 15, 20, 25, 30, 40, 50, 60
and 70 μM.2.5. Protein isolation and Western blotting
Hemibrains from WT and 5xFAD mice were homogenized in a
guanidine-thiocyanate-based buffer (RLT buffer, Qiagen) as described
above (Section 2.2) and the protein was isolated using the All Prep
DNA/RNA/protein isolation kit (Qiagen) following the manufacturer's
instructions. The protein pellet was resuspended in Laemmli's
SDS-PAGE loadingbuffer and incubated overnight at room temperature
prior to use. Alternatively, the proteinwas extracted from SH-SY5Y cells
as described previously [32].
In the case of N2aSw cells, soluble αAPP and Aβ peptide levels
were determined in harvested cell media [33]. The Aβ peptide was
immunoprecipitated from the medium overnight at 4 °C using the
2964 antibody [34] and Protein-A sepharose beads (Invitrogen). The
beads were then recovered by centrifugation (500 g, 5 min, 4 °C),
washed three times and diluted in Laemmli's buffer.
Protein samples (5–20 μg)were resolved on 16% (for brain samples)
or 4–12% (for cell culture samples) polyacrylamide gels, using Tris-
tricine or Tris-glycine electrophoresis buffer. The proteins were then
transferred to nitrocellulose membranes (GE, Amersharm) that were
subsequently blocked with 5% (w:v) non-fat dry milk in 0.1% (v:v)
Tween-20 PBS. These membranes were then probed overnight at 4 °C
with the corresponding primary antibody: anti-Aβ1-16 (clone 6E10,
1:4000; Signet Labs.), anti-Ser202/Thr205-PHF-tau (clone AT8,
1:1000; Pierce), anti-phospho-Ser202-tau (clone CP13; 1:1000;
kindly provided by Dr. Peter Davies, Albert Einstein College of Med-
icine, USA), anti-total-tau (Tau46; 1:2000; Pierce), anti-α-tubulin
(1:5000; Sigma). Antibody binding was detected with the IRDye-
800CW-labeled anti-mouse IgG for brain samples (1:5000; LI-COR
Inc.) or horseradish peroxidase-conjugated anti-mouse IgG for cell sam-
ples (1:2000; GE Healthcare). Membrane ﬂuorescence was detected
using anOdyssey Infrared Imaging System (LI-COR Inc.) andmembrane
chemiluminescence was detected by ECL (GE, Amersham) in an auto-
mated SRX 101A developer (Konica). The intensity of the bands was
quantiﬁed by densitometry using the Image J software (National
Institutes of Health) and normalized to α-tubulin.2.6. RNA isolation, reverse transcription and real time RT-PCR
RNA isolation, reverse transcription (RT) and quantitative real-time
PCR were performed according to the Minimum Information for publi-
cation of Quantitative real-time PCR Experiments (MIQE) guidelines
[35]. After homogenization in RLT-buffer (see Section 2.2), total RNA
was isolated from the brain using the All Prep DNA/RNA/protein
isolation kit (Qiagen) according to the manufacturer's instructions.
Residual DNA was removed by incubation with DNase (Qiagen) prior
to performing reverse transcription. RT was performed with the High
Capacity cDNA Archive kit (Applied Biosystems) on 4 μg of the total
RNA template, following the manufacturer's recommendations [36].
Human and mouse APP gene products were ampliﬁed from
5xFAD brain cDNA samples using speciﬁc primers: human/mouse
APP695 forward (5′-CATCATGGTGTGGTGGAG-3′), human APP695
reverse (5′-GCGATAATGAGTAAATCATAAAAC-3′) and mouse APP695
reverse (5′-GGGTGAGTAAATAAACGGAA-3′). For each assay, a standard
curve was ﬁrst deﬁned using increasing amounts of cDNA and in all
cases, the slope of these curves indicated the optimal ampliﬁcation efﬁ-
ciency (slope 3.2-3.4). GAPDHwas used as a control housekeeping gene
and this ampliﬁcation was detected by using commercial Taqman
probes (Mm99999915_g1; Applied Biosystems) according to the
manufacturer's instructions. GAPDH was ampliﬁed in parallel with the
target gene. The results were expressed using the comparative Ctmeth-
od, as described elsewhere [36,37]. As a control condition, we selected
mouse APP expression in WT mice. In consequence, the expression of
bothmouse and humanAPP genes, for allmouse strains and treatments,
was referenced to mouse APP expression levels observed in WT mice.
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Mouse neuroblastoma N2aSw cells were ﬁxed and permeabilized in
100%methanol at−20 °C for 20 min, the cells were then rehydrated in
PBS for 10 min and blocked in 1% BSA in PBS for 20 min at room
temperature. Subsequently, the cells were incubated with the primary
antibody diluted in 1% BSA in PBS overnight: mouse anti-APP (clone
6E10, 1:200; Signet Labs.), rabbit anti-BACE-1 (1:50; Cell Signaling),
rabbit anti-APP-C-terminal (R1(57); kindly provided by Dr P. Mehta,
New York State Institute for Basic Research in Developmental Disabil-
ities, USA); mouse anti-Lamp-1 (1:200; Abcam) and/or rabbit anti-LC3
(1:200; Abcam). The cells were then washed 3 times with PBS, and in-
cubated with Alexa 488 and 594-conjugated secondary antibodies
(Invitrogen) at room temperature in the dark. After 3 washes with
PBS, the coverslips weremounted onto slides using Vectashield mount-
ing solution containing DAPI (Vector Labs) and images were captured
on a Leica LAS AF SP5 confocal microscope. N2aSw cells transfected
with PS1-GFP were also permeabilized, rehydrated and analyzed as
above.
MDCK cells expressing APP-GFP were ﬁxed with 4% paraformalde-
hyde (Sigma) for 30 min and mounted onto slides using Vectashield
mounting solution (Vector Labs). Images were captured by confocal
microscopy (Becton Dickinson) and the number of ﬂuorescent APP-
containing vesicles per cell was calculated with AttoVision software
(Becton Dickinson).2.8. Amyloid-β42 peptide preparation
Monomeric, oligomeric and ﬁbrillar Aβ were prepared as described
previously [38]. An Αβ42 stock solution was prepared by dissolving
the peptide at 1 mg/ml in hexaﬂuoro-2-propanol (HFIP; Sigma) to ren-
der the Aβmonomeric. HFIPwas removed under vacuum in a SpeedVac
(Millipore) and the peptide ﬁlm was stored desiccated at−20 °C. For
the Aβ42 monomer preparation, the peptide ﬁlm was resuspended in
DMSO just prior to use at a concentration of 5 mM and it was sonicated
for 10 min in a bath-type ultrasound device. Oligomeric Aβwas gener-
ated bydiluting themonomeric preparation to 100 μMin 150 mMNaCl,
1 mMEDTA, 10 mMTris–HCl [pH 7.4], whichwas incubated for 24 h at
4 °C. Finally, ﬁbrillar Aβ was generated by adding 10 mM HCl to the
initial solution of monomeric Aβ to obtain 100 μM Aβ [pH 2.0], and
this solution was then incubated for 48 h at 37 °C.2.9. Aβ binding assays to lipid vesicles
2.9.1. Preparation of lipid vesicles
Large unilamellar vesicles (LUVs) were generated as described pre-
viously [39]. LUVs composed of sphingomyelin (SM) and Cho (1:1 mol
ratio) or SM:Cho:OHDHA (1:1:0.1 mol ratio) were extruded in 10 mM
Hepes, 1 mM EDTA, 100 mM NaCl [pH 7.4] using an extruder with
200 nm ﬁlters. The lipid composition of LUVs was quantiﬁed as de-
scribed previously [40], showing that the ﬁnal composition did not dif-
fer signiﬁcantly from the initial lipid mixture.2.9.2. Isothermal Titration Calorimetry (ITC)
ITC measurements were performed in a VP-ITC Micro-calorimeter
(MicroCal, Inc., Northampton, USA) as described previously [41,42].
Brieﬂy, the experiments were set-up with 23 μM of Aβ peptide (mono-
mer, oligomer or ﬁbrils) in the cell at 37 °C (cell volume: 1.4 ml) and
35 mM of LUV in the syringe. Thirty injections of 10 μl were adminis-
tered at an interval between injections of 10 min. All the thermodynam-
ic parameters were calculated using MicroCal Origin software. The
binding constant Ka (Kd = 1 / Ka) and enthalpy (ΔH) were obtained
from the ﬁtting of ITC isotherms, and the Gibbs free energy (ΔG) andentropy (ΔS) of binding were determined from the expression:
ΔG ¼ ΔH−ΤΔS ¼−RT ln Ka
where R is the gas constant and T is temperature.
2.10. Cell viability (MTT)
Cell viability was determined using the MTT (methyl-thiazolyl
diphenyl tetrazolium bromide) method, as described previously [32].
The MTT reagent (Sigma) was diluted to a ﬁnal concentration of
0.5 mg/ml in PBS and added to the cell culture for 2 h. Mitochondrial
dehydrogenases in viable cells reduced the tetrazolium salt, yielding
water insoluble colored formazan crystals. The MTT reagent was then
removed and the formazan crystals solubilized by adding one volume
of DMSO for 5 min, and after gentle shaking, the absorbance of the
solution was determined at 570 nm.
2.11. Zebraﬁsh embryo toxicity
Evaluation of OHDHA toxicity in zebraﬁsh embryos was performed
as described previously [43] and following the OECD (Organization for
Economic Co-operation and Development) Draft Guidelines. Brieﬂy,
ﬁve concentrations of OHDHA were added to different tanks of water:
1, 3, 10, 30 and 100 mg/l. The OHDHA was primarily dissolved in
DMSO to obtain the working stocks, keeping the ﬁnal concentration of
DMSO always below 0.1% in the toxicity assays. Each concentration of
OHDHA was tested in 20 individual embryos for 24, 48 and 72 h at
25 °C. After incubation, the percentage of embryos showing embryo
mortality, sub-lethal effects, teratogenic effects and viability was
determined.
2.12. Statistical analysis
Datawere expressed as themean ± SEM. Comparison between two
groups of data was performed using a two-tailed t-test. For comparison
between several groups, we used one-way ANOVA followed by Tukey's
post hoc multiple comparisons (Statgraphics plus 3.1). The level of
signiﬁcance was set at 95% of conﬁdence (p b 0.05).
3. Results
3.1. Effects of OHDHA on membrane lipid composition in the brains of
5xFAD mice
Themembrane lipid species in the brains ofWT, 5xFAD andOHDHA-
treated 5xFADmice were analyzed by lipidomic analysis (Fig. 1, Table 1
and Fig. S1). The most abundant lipid species detected were the differ-
ent classes of PE (see Fig. S1), with all PE species together constituting
approximately half of the total membrane lipids in the brain of WT
mice (47.77 ± 4.26%). A signiﬁcant increase in total PE levels in the
brain of 5xFAD mice was observed after treatment with OHDHA
(47.26 ± 6.11% increase with respect to untreated 5xFAD mice), and
these OHDHA-treated mice also showed higher PE levels compared to
WT mice (43.80 ± 5.96%; Fig. 1A). In addition, the elevated PE levels
in the brain of OHDHA-treated mice were due to a general increase in
all analyzed PE species (Fig. S1).
Treatment with OHDHA also increased the concentration of PUFA-
containing phospholipids (containing 5 or more double bonds, e.g.
DHA or EPA-containing phospholipids) compared to WT and 5xFAD
untreated mice, whereas it had a smaller impact on saturated fatty
acid-containing phospholipids (Figs. 1B and C). The higher level of
PUFA -containing phospholipids in the brain of 5xFADmice wasmainly
due to the increase in PE species provoked by OHDHA (see Table 1). In
this sense, the most important increase among diacyl-PE subspecies
was observed in PE 40:6 (an 85.2 ± 8.7% increase with respect to the
Fig. 1. Effect of OHDHA onmembrane lipid composition in the brain of 5xFADmice. Bar diagrams show the relative change in lipids in OHDHA-treated (dark gray bars) and control 5xFAD
mice (light gray bars) compared to the WT (considered as 100%, ﬁlled bars). LC/MS was used to analyze the levels of: (A) phosphatidylethanolamine (diacyl-PE, lyso-PE and their
plasmalogens), (B) polyunsaturated phospholipids (containing 5 or more double bonds), (C) saturated phospholipids, (D) phosphatidylcholine (diacyl-PC, lyso-PC and their
plasmalogens), (E) phosphatidylinositol (diacyl-PI), (F) phosphatidylserine (diacyl-PS and lyso-PS), (H) sphingolipids (sphingomyelin and dihydrosphingomyelin) and (I) ceramides (cer-
amide, lactosyl-ceramide and hexosyl-ceramides); and (G) cholesterol levelswere determinedby an enzymatic colorimetricmethod. These data showed a signiﬁcant increase in PE, PI and
PUFA-containing phospholipids in OHDHA-treated 5xFADmice compared with 5xFAD andWT control mice (panels A, B and E, respectively). No remarkable differences between 5xFAD
andWT samples were observed for any of the lipids studied. Bars show themean value from 3 animals ± SEM and the statistical analysiswas performed by one-way ANOVA and Tukey's
post hoc multiple comparison: *, p b 0.05.
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important elevations in the brain of 5xFADmice after OHDHA treatment
(40:5, 38:5, 38:4, 36:5 and 36:4; Table 1). This result is compatible with
the elevated levels of DHA in lipid membranes after OHDHA treatment
since diacyl-PE 40:6 may be constituted principally by 22:6 (DHA) and
18:0 fatty acids. Indeed, our lipidomic analysis also revealed that lyso-
PE 18:0 is the most abundant subspecie among all the lyso-PE lipids
(not shown), such that the diacyl-PE 40:6 detected must carry DHA at
position C2 of glycerol.
In the same context, an analysis of the hydrocarbon chain length of
Table 1-showed diacyl-PE subspecies revealed that long (40C) and me-
dium (36–38C)-chain-fatty acid-containing PEs increased more strong-
ly in the brain of 5xFAD mice after OHDHA treatment than short-chain
(32–34C) fatty-acid-containing PEs (a 50.59 ± 8.04% and 40.47 ±
7.04% increase, respectively, compared to theWT). Again, no signiﬁcant
differences were observed when comparing WT and 5xFAD control
mice (Table 1). All these data demonstrate that OHDHA produces an
elevation in the PE phospholipids in the brain of 5xFAD mice that
preferentially contain long/middle polyunsaturated acyl chains (40:6,
40:5, 38:5, 38:4, 36:5 and 36:4).
Finally, a signiﬁcant increase in the levels of phosphatidylinositol
(PI) in the brain of 5xFAD mice was also associated with OHDHA treat-
ment (Fig. 1E). By contrast, no signiﬁcant changes were observed in
other phospholipid species, such as phosphatidylcholine (PC) or
phosphatidylserine (PS: Figs. 1D and F), nor were there signiﬁcantdifferences in other lipid classes, such as cholesterol, sphingolipids
(sphingomyelin and dihydrosphingomyelin) and ceramides (ceramide,
hexosyl-ceramides and lactosyl-ceramide) (Figs. 1G, H and I, respective-
ly). However, the higher levels of PE in the brain of OHDHA-treated
mice induced modest general decreases in other lipids, such as Cho,
diacyl-PC and SM (see Fig. S1). In conclusion, changes in lipid mem-
brane composition induced by OHDHA may inﬂuence the lipid mem-
brane structure, provoking the formation of liquid disordered prone
structures [44].
3.2. OHDHA treatments induce a reduction in Aβ levels and tau protein
phosphorylation in transgenic 5xFAD mice and cellular models of AD
The production and accumulation of Aβ is one of the most studied
neuropathological features of AD. The accumulation of Aβ correlates
strongly with synaptic degeneration, and with memory and learning
deﬁcits in the 5xFADmodel [23,45,46]. Indeed, serious cognitive deﬁcits
were reported previously in thesemicewhen cognitive impairmentwas
analyzed using the radial arm maze test, as reﬂected by the increase in
the time spent in completing the test and the number of errors com-
pared to WT mice [19]. On the other hand, enzymes implicated in the
amyloidogenic route (β- and γ-secretases) are both integral membrane
proteins that are highly regulated by the membrane lipid environment
[47,48]. In this context, we hypothesized that OHDHA-mediated mem-
brane lipid modiﬁcations might inﬂuence Aβ generation/accumulation
Table 1
LC/MS characterization of diacyl-PE acyl chains in the brain of OHDHA-treated 5xFAD mice.
Diacyl-PE subspecies WT 5xFAD 5xFAD + OHDHA
Meana SEMa Meana SEMa % changeb Meana SEMa % changeb
Short acyl chains 32:0 112 3 105 3 −6.3 ± 3.0 NS 134 3 19.6 ± 3.0 **
32:1 168 4 205 39 22.2 ± 22.9 NS 240 13 42.5 ± 7.7 NS
34:1 2197 148 1817 71 −17.3 ± 3.2 NS 3030 188 37.9 ± 8.5 **
34:2 326 25 372 71 14.4 ± 21.7 NS 402 17 23.5 ± 5.4 NS
Subtotal 2803 154 2500 85 −10.7 ± 3.0 NS 3805 216 35.7 ± 7.7 **
Medium acyl chains 36:1 3862 477 3332 185 −13.7 ± 4.8 NS 5426 204 40.5 ± 5.3 **
36:2 3108 195 2584 98 −16.9 ± 3.2 NS 4319 210 39.0 ± 6.8 **
36:3 274 30 254 27 −7.2 ± 9.9 NS 303 22 10.4 ± 8.2 NS
36:4 3184 454 3416 465 7.3 ± 14.6 NS 5390 352 69.3 ± 11.0 *
36:5 201 16 318 69 58.8 ± 34.6 NS 295 11 46.9 ± 5.5 *
38:1 588 12 441 50 −24.9 ± 8.5 NS 713 53 21.4 ± 9.0 *
38:2 547 18 389 6 −28.8 ± 1.0 * 593 57 8.5 ± 10.4 NS
38:4 16,804 2171 16,670 1969 −0.8 ± 11.7 NS 24,716 1072 47.1 ± 6.4 *
38:5 2799 135 2903 143 3.7 ± 5.1 NS 4579 90 63.6 ± 3.2 ***
38:6 13,444 2330 12,244 821 −8.9 ± 6.1 NS 16,532 1412 23.0 ± 10.5 NS
38:7 244 30 340 100 38.9 ± 40.8 NS 425 19 73.7 ± 7.6 NS
Subtotal 45,054 5749 42,891 3716 −4.8 ± 8.2 NS 63,290 3171 40.4 ± 7.0 *
Long acyl chains 40:1 174 13 106 17 −38.9 ± 9.7 NS 160 23 −8.0 ± 13.0 NS
40:3 2768 369 2764 315 −0.2 ± 11.4 NS 4121 257 48.9 ± 9.3 NS
40:5 26,517 3064 26,194 2062 −1.2 ± 7.8 NS 38,945 2170 46.9 ± 8.2 *
40:6 3289 896 3901 785 18.6 ± 23.9 NS 6089 286 85.2 ± 8.7 *
Subtotal 32,747 4196 32,964 3137 0.7 ± 9.6 NS 49,314 2633 50.5 ± 8.0 *
Total 80,605 10,036 78,356 6833 −2.8 ± 8.5 NS 116,411 10,334 44.4 ± 7.4 *
Multiple statistical analysis was performed with one-way ANOVA & Tukey's post hoc test. NS: not signiﬁcant, * p b 0.05, ** p b 0.01 and *** p b 0.001.
a The measure of diacyl-PE subspecies (mean ± SEM) shown as pmol of lipid/mg of protein.
b The relative change in 5xFAD or OHDHA-treated 5xFAD brains relative to the mean WT value is shown as the mean ± SEM.
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on Aβ production in 5xFAD brain samples. As expected, we only identi-
ﬁed monomeric Aβ peptide in 5xFAD brain samples (Fig. 2A, upper
panel), in which there was a modest, yet signiﬁcant downregulation of
Aβ levels following OHDHA treatment (Fig. 2A, middle panel). In addi-
tion, human APP transgene expression remained unmodiﬁed by
OHDHA in these samples (see Fig. S2), demonstrating that Aβ levels
are not affected by changes in human APP gene expression. In parallel
with the reductions in Aβ, OHDHA-treated 5xFAD mice also displayed
a signiﬁcant recovery of learning and memory capabilities compared
to the 5xFAD control mice, evident through the reduction in the time
spent and working/reference memory errors committed when com-
pleting the behavioral test (previously reported by [19], see discussion
below). Thus, these results suggest that the modiﬁcations of lipids in
brain membranes are associated with a decrease in Aβ levels and im-
proved cognitive scores in this AD model.
The effect of DHA (and probably OHDHA) on Aβ production is
strongly inﬂuenced by dietary lipid intake. Indeed, this effect might be
underestimated due to the presence of speciﬁc lipids in the diet that
stimulate amyloidogenesis [49]. Therefore, we further studied this
issue in a cellular model of neuroblastoma cells stably expressing the
Swedish-mutant form of APP (N2aSw). In this context, the Aβ produced
and secreted into the cell culturemediumwas immunoprecipitated and
analyzed by immunoblotting. Cell cultures were treated with 5 and
10 μM of OHDHA, which led to a drastic reduction in Aβ in the medium
over 24 h (Fig. 2B). We also determined the soluble APPα (sAPPα)
levels in the culture medium (Fig. 2B) and the full length APP (ﬂAPP)
in cell extracts (not shown) using the 6E10 antibody. Unlike previous
reports [12], we found no remarkable changes in either sAPPα or
ﬂAPP, suggesting that the non-amyloidogenic route is apparently unaf-
fected by OHDHA and that the changes observed in Aβ are not due to
the downregulation of human APP expression. These data conﬁrmed
our previous results in the brain of OHDHA-treated 5xFAD mice.
On the other hand, tau phosphorylation was tested in the brain of
5xFAD mice at Ser202/Thr205 (AT8 epitope) and Ser202 (CP13 epi-
tope). Interestingly, AT8 antibody retrieved none or very low signal
when using these brain samples (not shown). However, when usingCP13 antibody our experiments showed a clear band of ca. 64 kDa,
especially in 5xFADmice (Fig. 2A, upper panel). Indeed, tau phosphory-
lation in 5xFAD brain samples was statistically increased compared to
WT controls, whereas this increase was prevented in OHDHA-treated
5xFAD mice (Fig. 2A, lower panel). Furthermore, total tau levels were
determined with Tau46 antibody in these samples. Labeling with this
antibody showed several speciﬁc bands ranging from 49 to 73 kDa
(probably corresponding to different phosphorylated forms of tau
protein) (Fig. 2A, upper panel). Minimal differences in total tau were
found and, consequently, phospho/total tau ratio showed similar
differences among WT, 5xFAD and OHDHA-treated 5xFAD mice
to those shown by phospho-Ser202-tau (Fig. 2A, lower panel). We
also tested the efﬁcacy of OHDHA in reducing the Aβ-mediated
hyperphosphorylation of tau in a cellularmodel of neuron-like differen-
tiation of SH-SY5Y cells [30]. For these assays, differentiated neuron-like
cells were stimulated for 24 h with oligomeric Aβ (5 μM) to induce tau
hyperphosphorylation in the presence or absence of OHDHA (5 and
10 μM). The addition of Aβ strongly induced tau phosphorylation at
Ser202/Thr205 (AT8epitope), although thepresence ofOHDHAmarkedly
and signiﬁcantly reduced the effect of Aβ on tau phosphorylation, which
was similar to that found in unstimulated controls (Fig. 2C). Consequent-
ly, OHDHA appears to inhibit Aβ-induced tau hyperphosphorylation.
Although there is strong evidence that membrane lipids participate
in the amyloidogenic pathway, the mechanism by which DHA or
OHDHA regulates Aβ generation still remains largely unknown. To de-
termine whether OHDHA affects the levels and distribution of ﬂAPP,
as well as the secretases responsible for amyloidogenic APP cleavage,
we evaluated the subcellular localization of APP, PS1 (the protein
containing the catalytic site of γ-secretase complex [50]) and BACE-1
(the principal β-secretase enzyme in the brain [51]) in N2aSw cells. In
these assays, N2aSw cells were treated with OHDHA (10 μM) for 24 h,
and the subcellular distribution of APP and BACE-1 was analyzed by
immunoﬂuorescence with the 6E10 and anti-BACE1 antibodies, respec-
tively (Fig. 3, panels A1 and A2 or A5 and A6, respectively). The distribu-
tion of PS1 was visualized in N2aSw cells transfected with PS1-GFP
cDNA (Fig. 3, panels A3 and A4). A diffuse distribution of APP, PS1 and
BACE was observed in the cytoplasm and Golgi apparatus of N2aSw
Fig. 2.OHDHA diminishes the β-amyloid brain pathology and tau hyperphosphorylation. (A) Representativewestern blots showingmonomeric Aβ, phospho-tau (Ser-202; CP13 epitope)
and total tau (Tau46) in 5xFAD brain samples (samemice used in Fig. 1)with tubulin-α used as a loading control (upper panel).Western blot quantiﬁcation showed a signiﬁcant decrease
in Aβ in the brain of 5xFAD mice that received OHDHA (middle panel). In the same way, quantiﬁcation of phospho and total tau revealed a signiﬁcant increase in phospho-tau levels in
5xFAD thatwasmajorly prevented inOHDHA-treated 5xFADmice, as comparedwithWT,whereas total-tau levels did not showany signiﬁcant differences. Consequently, the phosho/total
tau ratio was showed signiﬁcantly increased in 5xFAD but not in OHHDA-treated 5xFAD mice, as compared with WT (lower panel) (bars show the mean value from 3 animals ± SEM).
(B) Representative western blot of Aβ and sAPPα in N2aSw cell culture media (upper panel). Western blot quantiﬁcation revealed that exposing N2aSw cells to OHDHA (10 μM) for 24 h
drastically reduced Aβ production without altering sAPPα levels (n = 3) (lower panel). (C) Representative western blot of tau hyperphosphorylation in neuron-like differen-
tiated SH-SY5Y cells (upper panel). Western blot quantiﬁcation showed a strong induction of tau phosphorylation at the AT8 epitope after Aβ stimulation, whereas addition of OHDHA
(5 μM)partly reduced Aβ-mediated tau phosphorylation and it was completely abolished in the presence of OHDHA (10 μM; n = 3) (lower panel). #, p b 0.05 according to two-
tailed t-test between two groups; *, p b 0.05 according to multiple statistical analysis by one-way ANOVA and Tukey's post hoc test.
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and A5, respectively). Following exposure to OHDHA these proteins lo-
calized to deﬁned vesicle-like punctae (Fig. 3, panels A2, A4 and A6, re-
spectively), suggesting that OHDHA provokes the clustering of APP, PS1
and BACE-1 into deﬁned cell vesicles/organelles. These results indicate
that the recruitment of these proteins into cell vesicles actively partici-
pates in the OHDHA-mediated inhibition of amyloidogenesis (Fig. 2B).
In order to elucidate the possible implication of the endolysosomal sys-
tem on APP/PS1/BACE-1 vesicle recruitment and Aβ level downregula-
tion in OHDHA-treated N2aSw cells, we further studied the nature of
these vesicles by confocal immunoﬂuorescence co-localization of APP
and LC3 (autophagic vesicle marker), or APP and Lamp1 (lysosome
marker). Our results clearly showed no co-localization between APP
and LC3, whereas APP and Lamp1 showed some weak co-localization
in OHDHA-treated cells (Fig. S3), suggesting that the origin of these
APP-positive vesicles is not the autophagic or lysosomal system. On
the other hand, these results were conﬁrmed in MDCK cells stably
expressing the APP-GFP fusion protein, where the clustering of APP
alone was shown to be induced by OHDHA over a wider range of con-
centrations (Fig. 3B, testing exposure to 1, 3, 10, 15, 20, 25 and 30 μM
OHDHA for 72 h). These results conﬁrmed the effect previouslyobserved in N2aSw cells, as APP clustering in vesicles ﬁrst appeared in
the presence of 10 μM OHDHA, and it was more prominent at 15,
20 and 25 μM (Fig. 3, panels B1, B2, B3 and B4, respectively). Thus,
GFP-positive vesicles rapidly accumulated and this effect became satu-
rated between 20 and 30 μM, indicating a reduced amyloidogenic
secretase activity in OHDHA-treated MDCK cells. Indeed, quantifying
the ﬂuorescent vesicles allowed the half maximal effective concentra-
tion (EC50) to be determined as 17.8 μMunder these experimental con-
ditions (Fig. 3, panel B5).
3.3. Neuroprotective effect of OHDHA on neuron-like differentiated cells
exposed to an Aβ or a NMDA-mediated toxic insult
Our results demonstrate that OHDHA regulates the lipid composi-
tion ofmembranes, aswell as Aβ accumulation and tauphosphorylation
in the brain of 5xFAD mice, suggesting a possible neuroprotective role
for OHDHA. Therefore, we studied whether OHDHA might promote
neuron survival by examining the response of human neuroblastoma
SH-SY5Y cells and embryonic stem P19 cells differentiated to a
neuron-like phenotype when confronted by known neurotoxic com-
pounds. First, neuron-like cells differentiated from SH-SY5Y cells were
Fig. 3. Subcellular distribution of APP, PS1 and BACE1 inN2aSw (APPsw) andMDCK (APP-GFP) cell cultures treatedwith OHDHA. (A) Confocal images showingN2a cells stably expressing
Swedish APP. Cells were immunolabeled with the 6E10 antibody to detect APP (panels A1–A2), with an anti-BACE1 antibody (panels A5–A6) or transfectedwith a PS1-GFP vector (panels
A3–A4). Immunoﬂuorescence assays showedAPP, BACE-1 and PS1 cluster in cell vesicles/organelles following OHDHA treatment (panels A2, A4 and A6, respectively) as compared to con-
trol cells (panels A1, A3 and A5, respectively). (B) Confocal images of MDCK cells stably expressing APP-GFP and exposed to increasing concentrations of OHDHA (B1: 10 μM; B2: 15 μM;
B3: 20 μM;B4: 25 μM). Vesicular accumulation of APP-GFP conﬁrmedprevious resultswithN2aSw cells (panel A2). APP clusteringwas evident in thepresence of OHDHA (10 μM)and the
number of GFP-positive vesicles rapidly increased at higher concentrations until saturation. Fluorescent vesicle quantiﬁcation showed an EC50 value of 17.8 μM (B5). Scale bars: 10 μm
(A1–A6) and 20 μm (B1–B4).
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of OHDHA, and cell viability was determined with the MTT assay.
Exposure to Aβ42 reduced cell viability by 20.48 ± 1.18% and while
neuronal death caused by Aβ was inhibited in the presence of 5 μM
OHDHA, in the presence of 10 μM OHDHA the number of neuron-like
cells was even greater than that of the control cells not exposed to Aβ
(37.85 ± 1.55% over untreated control cells: Fig. 4A). Similarly,
NMDA-induced Ca2+ excitotoxicity caused a reduction in the number
of P19-derived cells (a 39.42 ± 6.24% loss compared to untreated con-
trol cells: Fig. 4B). In this context, exposure to OHDHA (10 μM, 24 h)
induced an increase in the number of viable cells with respect to
NMDA-treated and untreated control cells (133.58 ± 32.26% and
94.36 ± 32.26%, respectively: Fig. 4B). These results demonstrated
the neuroprotective effect of OHDHA against oligomeric Aβ and
NMDA-mediated excitotoxicity, and suggest that OHDHA may even
induce neuronal proliferation [19].
To further investigate the mechanism by which OHDHA offers neu-
roprotection against oligomeric-Aβ-mediated toxicity, we carried out
model membrane-based assays to analyze the binding of different ag-
gregated forms of Aβ to lipid-raft-like vesicles composed of Cho and
SM. We chose this type of vesicles because lipid-raft membrane do-
mainshave beendescribed as the loci of Aβ generation and binding,me-
diating Aβ cellular toxicity [42,53,54]. We observed that the binding of
monomeric Aβ to raft-like bilayers only occurred in the presence of
OHDHA (Table 2A), while the afﬁnity of Aβ oligomers for raft-likemem-
branes was lower in the presence of OHDHA (ca. 8 fold reduction:
Table 2B). Moreover, the afﬁnity of Aβ ﬁbrils for raft-like membranes
was reduced by ca. 160 fold in the presence of OHDHA (an increase in
the Kd value from 4.76 to 775 μM: Table 2C). These results clearly indi-
cate that OHDHA favors the interaction of monomeric Aβwith raft-likemembranes and that OHDHA impairs the interaction of oligomeric/ﬁ-
brillar Aβ with membranes. These effects might explain the neuropro-
tection provided by OHDHA against oligomeric-Aβ-mediated toxicity
in neuron-like cells (see Fig. 4A).
3.4. Evaluation of OHDHA toxicity in zebraﬁsh embryos
The data presented here suggests that OHDHA is a therapeutic can-
didate for AD. For this reason, we tested the safety of OHDHA as a
drug for human administration by evaluating its lethal, sub-lethal and
teratogenic effects in zebraﬁsh embryos. We tested zebraﬁsh embryo
mortality and viability on exposure to OHDHA at 1, 3, 10, 30 and
100 mg/l (2.7, 8.1, 27.3, 81.8 and 273 μM, respectively) for 24, 48 and
72 h, as well as measuring its sub-lethal and teratogenic effects. Sub-
lethal effects were considered to include the lack of spontaneous move-
ment, pigmentation deﬁcits and edema or clots in organs or other
internal structures, while teratogenic effects included deformation of
organs or internal structures, scoliosis and general growth delay (see
Table 3). OHDHA had only a mild effect on embryo mortality at the
highest concentrations tested (100 mg/l), producing 20% mortality up
to 48 h and 35% after a 72-hour exposure (Table 3A). Accordingly,
embryo viability was tested at 72 h and negative effects were only pro-
duced on exposure to 100 mg/l OHDHA, whereas lower concentrations
(1 to 30 mg/l) were correlated with acceptable levels of embryo viabil-
ity (between 80 and 100%: Table 3B). Similarly, sub-lethal effects were
only observed at high concentrations of OHDHA (100 mg/l), and in a
time-dependent manner (from 56 to 77%, between 48 and 72 h),
whereas no remarkable effects were observed at lower concentrations
(Table 3C). It should be noted that in all cell culture experiments per-
formed in the present work, OHDHA was used at concentrations
Fig. 4. OHDHA protected cells with a neuron-like phenotype against an Aβ or a NMDA-
mediated toxic insult. (A) SH-SY5Y cells were differentiated into neuron-like cells and
treated with oligomeric Aβ peptide (5 μM) for 24 h in the presence or absence of
OHDHA (5 and 10 μM). The MTT assay was used to quantify the number of viable cells/
well. Oligomeric Aβ reduced cell viability but the number of viable cells was recovered
upon OHDHA treatment to the untreated control values (5 μM OHDHA) or even higher
(10 μM OHDHA; n = 3). (B) P19 embryonic stem cells were differentiated into neuron-
like cells and exposed to NMDA (in the presence of 10 mM Ca2+). Concomitant OHDHA
treatment reduced NMDA/Ca2+-induced cell death and even increased the number of vi-
able cells above that of the untreated controls (n = 3). #, p b 0.05 according to two-tailed
t-test between twogroups; *,p b 0.05 compared toAβ- orNMDA-treated controls, accord-
ing to multiple statistical analysis by one-way ANOVA and Tukey's post hoc test.
Table 2
OHDHA incorporation into lipid raft-like vesicles inhibits binding of Aβ oligomers and
ﬁbrils.
SM/Cho/OHDHA a SM/Cho a
(1:1:0.1 mol ratio) (1:1 mol ratio)
A. Monomer
Kd (μM)b 58 ± 7.7 No interaction
ΔH (Kcal/mol)b −3.31 ± 0.24 detected
ΔS (cal/mol.°C)b 8.7 ± 0.5 –
ΔG (Kcal/mol)b −6.01 ± 0.40 –
B. Oligomer
Kd (μM)b 21.6 ± 2.8 *** 2.7 ± 0.9
ΔH (Kcal/mol)b −1.06 ± 0.98 ** −2.11 ± 0.09
ΔS (cal/mol.°C)b 17.9 ± 3.2 18.6 ± 2.5
ΔG (Kcal/mol)b −6.61 ± 1.10 −7.80 ± 0.40
C. Fibrils
Kd (μM)b 775 ± 52 *** 4.76 ± 0.11
ΔH (Kcal/mol)b −2.77 ± 0.24 *** −0.87 ± 0.06
ΔS (cal/mol.°C)b 5.3 ± 0.9 ** 21.6 ± 1.2
ΔG (Kcal/mol)b −4.41 ± 1.00 * −7.56 ± 1.50
The data are expressed as the mean ± SEM. Statistical analysis was performed by two-
tailed t-test: * p b 0.05, ** p b 0.01 and *** p b 0.001.
a Large unilamellar vesicles composed of SM and Cho, plus/minus OHDHA, were used
for isothermal calorimetric titration, together with different forms of Aβ42 peptide: (A)
monomeric, (B) oligomeric and (C) ﬁbrillar (n = 3).
b The parameters measured in the assay: Kd (dissociation constant), ΔH (enthalpy
change), ΔS (entropy change) and ΔG (Gibbs free energy change) were obtained as
described in the Section 2.9.
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duce teratogenic effects after long-term incubation (72 h), whereas
only the highest concentration (100 mg/l) could induce teratogenic ef-
fects within 24 h (Table 3D). The main teratogenic effects observed
were organ deformation and growth delay. However, in an elevated
proportion of these embryos these effects reverted after longer expo-
sures, even at high concentrations. Speciﬁcally, in the presence of
100 mg/l OHDHA the percentage of affected embryos decreased from
100% at 24 h to 38% at 72 h, suggesting that these teratogenic effects
might be an acute response to the treatment but theywere not so severe
as to be maintained for an extended period.
Finally, we tested OHDHA toxicity in WT and 5xFAD mice by moni-
toring their weight, which increased throughout the treatment period
except when they were maintained on a hypocaloric diet during the
behavioral testing (Fig. S4). This result suggested that OHDHA is not
toxic at therapeutic doses. Indeed, no mortality or relevant physical
side-effects (hair loss, behavioral alterations like jumping or itching,
etc.) were observed in association with OHDHA treatment, further sug-
gesting that this drug is unlikely to produce toxicity when administered
long-term to mice.4. Discussion
Despite the efforts to discover a plausible and effective treatment for
AD, no such therapies for this devastating disorder are as yet available.
On the one hand, current therapies used for AD treatment have poor
clinical efﬁcacy, such as the administration of acetylcholinesterase in-
hibitors andNMDA receptor antagonists. On the other hand, drug devel-
opment has mainly focused on disease-modifying strategies, such as
targeting the two neuropathological features that characterize AD and
that are thought to play a central role in the neurodegeneration process:
amyloid-β accumulation and tau hyperphosphorylation [55,56].
However, these therapeutic approaches have also failed [1], including
a phase III trial with the anti-Aβ antibody bapineuzumab (Pﬁzer,
ClinicalTrials.gov reference # NCT00998764). In contrast, hydroxyl de-
rivatives of docosahexaenoic acid have been found in nature and
many of them are neuroprotective such as resolvins and protectins
[20,21,57,58]. In this sense, OHDHA has been shown to induce recovery
of the cognitive status in an AD mouse model [19] and our present re-
sults suggest that this hydroxyl-DHA derivative constitutes a promising
therapeutic alternative.
Several mechanisms have been proposed to explain the neurode-
generation associated with AD. Here, we have focused on membrane
lipid changes that occur during AD as possible signals that trigger both
neurodegeneration and the other neuropathological features associated
with AD. In this sense, low levels of DHA and of PE, the principal phos-
pholipid containing this fatty acid in the brain, have frequently been re-
ported in AD [8,9,59–61]. However, DHA administration in patients
with mild-to-moderately severe AD produced inconclusive results in
clinical trials, highlighting the need to adopt different DHA-based
therapeutic strategies. Here, we propose an alternative therapeutic ap-
proach based on membrane lipid targeting with OHDHA. Indeed, we
previously demonstrated that OHDHA is able to improve the cognitive
deﬁcits in the 5xFAD mice (time and working/reference memory er-
rors), as well as increasing basal neurogenesis in the hippocampus of
these transgenic mice to WT levels (see Table 4) [19]. In this work, we
show that OHDHA canmodulate the brainmembrane lipid composition
Table 3
Evaluation of OHDHA toxicity in zebraﬁsh embryos.
OHDHA
(mg/ml)
Incubation (h)
24 48 72
A. Embryo mortality
1 0 0 0
3 0 0 0
10 0 0 0
30 0 0 10
100 20 20 35
B. Embryo viability
1 – – 100
3 – – 80
10 – – 80
30 – – 94
100 – – 46
C. Sublethal effects
1 0 0 0
3 0 0 0
10 0 5 5
30 0 10 0
100 0 56 77
D. Teratogenic effects
1 0 0 5
3 0 0 70
10 5 5 50
30 10 25 100
100 100 66 38
The data are expressed as the percentage of embryos that showed any of the parameters
studied: (A) embryomortality, (B) embryo viability, (C) sub-lethal effects: lack of sponta-
neous movements, pigmentation deﬁcits and apparition of edema or clots in internal
structures, and (D) teratogenic effects: deformation of internal structures, scoliosis and
general growth delay.
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cies, aswell as diminishingAβ generation in N2aSw cells and Aβ burden
in the brain of 5xFAD mice. Likewise, oral administration of OHDHA in-
hibits tau protein phosphorylation in the brain of 5xFAD mice and in
Aβ-treated neuron-like cells, and it enhances neuron-like cell viability
against oligomeric-Aβ and NMDA/Ca2+-mediated toxicity. Additional-
ly, OHDHA exhibited little pharmacological toxicity in vivo, and
zebraﬁsh embryos showed no remarkable alterations in terms of mor-
tality and sublethal effects at the doses used here.
OHDHA induced relevant lipid modiﬁcations in the brain of 5xFAD
mice that were the opposite of those reported for AD. Accordingly, our
lipidomic analysis showed an increase in all PE species (including
diacyl-PE, lyso-PE and their plasmalogens) and in polyunsaturated
acyl chains (phospholipids containing 5 or more double bonds), similar
to those produced by DHA in the mouse brain [62] or in human plasma
[63]. Speciﬁcally, increases in all diacyl-PE subclasses were observed,Table 4
Improved cognition and neurogenesis in OHDHA-treated-5xFAD mice.
WT 5xFAD
mean ± SEM mean ± SEM
Time (s) c 75.69 ± 4.77 124.4 ± 12.3
WME (number of errors) c 2.32 ± 0.32 3.95 ± 0.47
RME (number of errors) c 5.88 ± 0.39 8.31 ± 0.64
Phospho histone-H3 positive neurons (cells/mm3)d 7431 ± 1918 1970 ± 767.
The statistical analysis was performedwith a two-tailed t-test: * p b 0.05 and ** p b 0.01 after co
treated-5xFAD and 5xFAD control mice. Summary of data extracted from [19].
a Percentage change in 5xFAD control mice was expressed as the mean ± SEM relative to th
b The percentage change in 5xFAD + OHDHA was expressed as the mean ± SEM relative t
c Time (s), and the number of working and referencememory errors (WME andRME, respect
5xFAD + OHDHA, n = 12).
d Neuronal proliferation in the dentate gyrus (hippocampus) was determined by quantif
immunolabeled brain sections (WT, n = 4; 5xFAD n = 7 and 5xFAD + OHDHA, n = 7).although species containing long (40C) and medium length (36–38C)
acyl chains increased markedly with respect to shorter acyl chains
(32–34C). It is noteworthy that OHDHA caused the highest increase in
diacyl-PE 40:6 in the brain of 5xFAD mice, mainly formed by 22:6
(DHA) and 18:0 fatty acids. In addition, signiﬁcant increases in other
diacyl-PE subspecies were also evident in OHDHA-treated mice, such
as 40:5 and 38:5, which contain the omega-3 fatty acids 22:5 (DPA) or
20:5 (EPA) and that can be generated enzymatically from the 22:6
acyl chain [62,64]. In this context, the OHDHA-induced lipid modiﬁca-
tions should counteract the lipid deﬁcits associatedwith AD. Indeed, bi-
opsies from AD brains were characterized by the loss of diacyl-PE
subspecies (especially, 40:6, 38:6 and 38:4) and low levels of lipids con-
taining long acyl chains, along with an increase in species containing
short acyl chains in the human prefrontal cortex, among other lipid
alterations [65]. Fatty acid length and their degree of saturation are de-
terminant factors inﬂuencing membrane structure and functionality
[66]. Indeed, by adequately regulating membrane lipid composition
cell membranes may reverse the pathological changes in neurons, as
may be the case in AD [22]. On the other hand, no remarkable differ-
ences in lipids were found in the brain of the 5xFAD ADmice compared
to WT controls. However, other brain membrane lipid alterations have
been detected in different AD models [65,67] and there have been
many discrepancies between post-mortem AD tissue and AD model
brains, implying that AD models are likely not to faithfully reproduce
all the lipid alterations associated with AD [65,67].
We also demonstrated that OHDHA affects Aβ production in cul-
tured cells stably expressing Swedish APP and in the brain of 5xFAD
mice, consistent with previous observations for DHA in cultured cells
and in ADmodels [11,12,68]. In this context, membrane lipids canmod-
ulate the amyloidogenic route by acting on BACE-1 and the γ-secretase
complex [47,48,69]. The activity of these enzymes increases in raft-like
domains that are enriched in Cho and SM. PE, OHDHA and PUFAs can
change the membrane from a liquid ordered to a liquid disordered
state, which does not support amyloidogenesis [44,70,71], therefore,
cell membranes in the mouse brain or cultured cells that are exposed
to OHDHA should undergo such changes, dampening the activity of
the secretases implicated in Aβ generation. In addition, we demonstrat-
ed that OHDHA induces strong clustering of the APP, PS1 and BACE1
proteins into cellular vesicles/organelles. Although we have yet to
deﬁne the nature of these vesicles, these results suggest that OHDHA-
induced membrane lipid changes might regulate endolysosomal
proteolysis [72], and this mechanism of action may also contribute to
the downregulation of Aβ after OHDHA treatment. Interestingly, au-
tophagy/lysosomal proteolysis is impaired in AD and AD models, and
its stimulation has been proposed as a potentially effective therapeutic
strategy to combat AD [37,73–75]. However, our confocal microscopy
assays showed weak co-localization between APP and LC3, or APP and
Lamp1, in the vesicles observed after treatment with OHDHA in
N2aSw cells. Consequently, these results did not allow concluding the5xFAD + OHDHA
% changea mean ± SEM % changeb
8 64.35 ± 9.95 ** 105.4 ± 10.34 −15.27 ± 9.81 NS
70.25 ± 11.89 * 2.21 ± 0.40 −44.05 ± 18.09 §
41.32 ± 7.70 * 6.07 ± 0.73 −26.94 ± 12.02 §
1 −73.48 ± 38.93 * 5374 ± 939.7 272.79 ± 17.47 §
mparison betweenWT and 5xFAD; NS: not signiﬁcant and § p b 0.05 comparing OHDHA-
e WT as a reference.
o 5xFAD mice.
ively)were determined during the radial armmaze test (WT, n = 10; 5xFAD, n = 11 and
ying the number of phospho-histone H3-positive neurons in the granullar cell layer of
1690 M. Torres et al. / Biochimica et Biophysica Acta 1838 (2014) 1680–1692possible implication of the autophagy/lysosomal route as a molecular
mechanism mediating downregulation of Aβ levels in OHDHA-treated
N2a cells. Therefore, further analysis would be necessary to conﬁrm
this hypothesis and to identify the origin of these vesicles.
In addition, we demonstrated that OHDHA treatment protects
neuron-like cells against the AD-related toxicitymediated by oligomeric
Aβ or NMDA, and it prevented Aβ-induced tau hyperphosphorylation.
We provided here evidence that these phenomena may be explained
by the modiﬁcation of membrane lipid composition and structure by
OHDHA, for example the weaker afﬁnity of oligomeric and ﬁbrillar Aβ
for raft-like vesicles containing OHDHA observed in the ITC assays.
Moreover, OHDHA increases the relative abundance of polyunsaturated
lipid species, which might inhibit the interaction of Aβ oligomers with
lipid raft-associated protein receptors, thereby inhibiting their cytotoxic
cell signaling [76]. In this context, ITC assays also demonstrated that
monomeric Aβ exclusively interacted with raft-like vesicles in the
presence of OHDHA, suggesting that monomeric Aβ preferentially
binds to liquid disordered-prone structures [42]. Interestingly, the
persistence of monomeric Aβ is associated with neuroprotection,
supporting neuronal survival under conditions of trophic deprivation
and combating excitotoxicity. Furthermore, monomeric Aβ enhances
glycogen synthase kinase-3β (GSK-3β) phosphorylation, suggesting
that monomeric Aβ may downregulate tau phosphorylation [77].
Therefore, these results suggest that OHDHApromotes neuronal surviv-
al by favoring the membrane interactions of monomeric Aβ but not
those of oligomeric or ﬁbrillar Aβ (the presence of OHDHA induces ca.
170-fold reductions in the afﬁnity of ﬁbrils for lipid rafts). Nevertheless,
it cannot be ruled out that OHDHA may regulate APP processing by al-
tering themembrane lipid composition, limiting the ensuing alterations
originated by Aβ generation, such as Aβ oligomerization and tau
hyperphosphorylation. Moreover, NMDA-mediated Ca2+ excitotoxicity
also leads to neurodegeneration in AD [78,79] and this may also be re-
versed by OHDHA. However, the molecular mechanism connectingFig. 5. Postulated mechanism of action for OHDHA. Summary of the proposed molecular me
brain membranes in PE, especially those carrying DHA and other long PUFAs. These lipid chan
disordered-prone structures, and they might reverse the cellular signaling associated with
hyperphosphorylation; and (ii) decreasing neuron vulnerability to extracellular toxic agents su
duced proliferation of both neuron-like cells in vitro and neuron stem cells in the mouse brain.
that may be associated with the improved cognitive capabilities seen in the 5xFAD mouse modOHDHA-mediated membrane lipid changes and NMDA-receptor
trafﬁcking at synaptic terminals remains unknown.
Interestingly, exposingdifferentiatedneuron-like cells toOHDHA in-
creased the proportion of viable cells in culture in the presence of a toxic
insult (oligomeric Aβ or NMDA) even above that of control neuron-like
cells (not submitted to toxic insult), suggesting that OHDHA might
induce mitotic division of neuronal stem cells. Indeed, OHDHA in-
duced neuronal stem cell proliferation in the hippocampus of
5xFAD mice, as reﬂected by a remarkable increase in the number of
phospho-histone-H3-positive neurons (see Table 4) [19], although
the molecular mechanisms associated with this phenomenon remain
unknown. In summary, OHDHAnot only has a neuroprotective inﬂuence
on neuron-like cells but also, it exerts an apparent neuroregenerative ef-
fect in neuron-like cells in culture, and in the brain of 5xFADmice, both of
whichmight explain the enhanced cell survival, and the improved learn-
ing and memory capabilities of 5xFAD mice administered OHDHA.
AD is a complex neurodegenerative process that has been related to
lipid diet and to metabolic diseases. Indeed, this pathology is probably
driven by lipid alterations in neuronal membranes that lead to defective
APP processing, altered cell signaling and the ensuing events character-
istic of this pathology. In line with this, alterations in membrane lipids
(e.g., PE and DHA) of AD patients have been described previously [65],
although this fact has still not been taken into consideration when
designing other therapeutic strategies. In the present work, we have
investigated the molecular basis underlying the effects of OHDHA on
AD-associated cognitive loss. This “membrane lipid therapy”-based
drug is a molecule designed to target lipid membranes and regulates
the membrane-associated protein activity, which when altered may
cause neurodegeneration and eventually, AD. The beneﬁcial effects of
OHDHA include the restoration of cognitive scores in the 5xFAD
model of AD, the protection of cells against external AD-associated
toxic agents, such as oligomeric Aβ, and a reduction in the produc-
tion of Aβ and tau hyperphosphorylation (Fig. 5). In conclusion,chanisms underlying the effects of OHDHA on neuronal membranes. OHDHA enriches
ges may inﬂuence the structure of the cell membrane, leading to the formation of liquid-
AD by: (i) downregulating amyloidogenic processing and Aβ-dependent tau protein
ch as oligomeric Aβ and NMDA/Ca2+-mediated excitotoxicity. In addition, OHDHA also in-
Together, this evidence supports a neuroprotective and neuroregenerative role of OHDHA
el.
1691M. Torres et al. / Biochimica et Biophysica Acta 1838 (2014) 1680–1692OHDHA constitutes a promising therapeutic compound to combat
AD-associated neurodegeneration.
5. Concluding remarks
AD is a neurological disorder with unmet clinical needs. In this work,
we proposed a 2-hydroxyl-derivative of DHA as a plausible alternative
therapeutic strategy to treat this pathology. This drug modiﬁes the
membrane lipid composition, causing a reduction in β-amyloid produc-
tion and normalization (i.e. reduction) of tau hyperphosphorylation, it
enhances neuron-like cell survival and hippocampal neurogenesis,
leading to improved cognitive function, as seen in the 5xFAD mouse
model of Alzheimer's disease.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamem.2013.12.016.
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